You are here: Industry Insights > Foundation Medicine

News List

Roche and Foundation Medicine reach definitive merger agreement to accelerate broad availability of comprehensive genomic profiling in oncology worldpharmanews
July 05, 2018
Roche (SIX: RO, ROG; OTCQX: RHHBY) and Foundation Medicine, Inc. (NASDAQ: FMI) have entered into a definitive merger agreement for Roche to acquire the outstanding shares of FMI's common stock not already owned by Roche and its affiliates at a price of US
Roche commences tender offer for all shares of Foundation Medicine, Inc. for US$ 137.00 per share in cash worldpharmanews
July 05, 2018
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Foundation Medicine, Inc.
Roche buys Foundation Medicine for $2.4 billion financialexpress
June 29, 2018
Swiss drugmaker Roche is paying $2.4 billion to buy the rest of Foundation Medicine (FMI), raising its bet on the US genomic profiling group’s ability to personalise cancer care.
Roche to buy remaining stake in Foundation Medicine for $2.4bn pharmaceutical-technology
June 28, 2018
Roche has signed a definitive agreement to acquire the outstanding shares of Foundation Medicine (FMI) for $2.4bn.
Roche buys out rest of Foundation Medicine for $2.4bn pharmafile
June 22, 2018
Roche has clearly seen significant potential in Foundation Medicine’s work in genomics to pay $2.4 billion to take complete ownership of the company.
Roche snaps up rest of Foundation Medicine for $2.4bn pharmatimes
June 21, 2018
Roche is buying the shares it does not already own in US molecular information company Foundation Medicine (FMI), in a deal valued at $2.4 billion.
Foundation Medicine’s New Liquid Biopsy Assay Granted Breakthrough Device Designation by U.S. Food and Drug Administration biospace
April 27, 2018
Foundation Medicine, Inc.today announced that the FDA granted a Breakthrough Device designation for its new liquid biopsy assay, which is an expanded version of its FoundationACT® assay.